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A report on the Sixth International Meeting of the
Microarray Gene Expression Data Society (‘MGED6’), Aix-
en-Provence, France, 6-8 September 2003. 
The sixth Microarray Gene Expression Data Society meeting
brought together computational and life scientists to discuss
microarray data management and analysis, developments in
microarray technology and functional genomics, and find-
ings resulting from the use of microarrays. The meeting, and
MGED itself, have come a long way since 1999 when Alvis
Brazma and Alan Robinson (European Bioinformatics Insti-
tute (EBI), Cambridge, UK) canvassed community opinion
to determine whether there was interest in establishing stan-
dards for microarray databases. Four years on, standards
have been put in place, data are being generated on a large
scale at a number of centers worldwide, and a wealth of tools
and databases have been developed. 
Data management
Many of the topics covered at MGED6 are not specific to
microarrays, but instead are pertinent to most high-through-
put functional genomics technologies. They have been
addressed by MGED because microarray technology was one
of the first to reach maturity and the benefits of data sharing
were appreciated at an early stage. The principal challenges
in dealing with large amounts of data relate to data analysis
and the establishment of commonly accepted standards for
data storage and description. How should the data be
described and what should be included in the description, so
that others in the field can either repeat the experiment, or
determine whether the conclusions are supported by the
underlying data? These challenges surfaced several years ago
as microarray data began to accumulate. It became clear that
not only was there great value in mining across very large
datasets, but that the data could be considered a phenotype,
a way of describing biological systems that transcends
species- and subject-specific boundaries. 
In response to these challenges, MGED established four
working groups with the remit of establishing standards for
data management (the MAGE group), the minimum infor-
mation that must be recorded to describe a microarray
experiment (MIAME), the terms used to describe an experi-
ment (Ontology) and the methods used for data analysis
(Normalization). To date, the working groups have rolled out
first versions of the MAGE object model and markup lan-
guage, the MIAME guidelines for data annotation and the
MGED ontology; these are being actively used by the com-
munity of data generators. The majority of talks at MGED6
either related to initiatives by one of the four working groups
or provided examples of how microarray data are being
used, particularly in a clinical setting. What is striking is the
extent to which the basic concepts underlying MAGE and
MIAME, in particular, are being extended by other groups to
cover domain-specific knowledge in a variety of fields. Talks
related to MIAME included ways in which the concept is
being extended or modified to cover subjects as diverse as
chromatin immunoprecipitation ‘on a chip’, toxicogenomics,
tissue arrays, environmental biology, single-nucleotide poly-
morphism (SNP) analysis and proteomics. Abstracts of talks,
lists of speakers, and the MGED6 handbook are freely avail-
able online [http://tagc.univ-mrs.fr/mged6]. 
All four MGED initiatives have been designed to support the
transfer of data into the public domain on publication (in
line with the accepted standards for non-high-throughput
data) and there are now three public repositories that accept
data in this format. Two of these repositories were repre-
sented at the meeting; Yoshio Tateno (National Institute of
Genetics, Japan) described CIBEX at the DNA Data Bank of
Japan, and Helen Parkinson (EBI) described ArrayExpress,
the microarray data repository at the EBI. ArrayExpress cur-
rently has information on 1,200 hybridizations (arrays) andsubmissions from 50 groups. Two thirds of the submissions
have come from 50 studies via data-transfer pipelines and
one third from small-scale users who have largely been
prompted to transfer their data into the public domain by
journals as a condition of publication. ArrayExpress now has
facilities for submitting data prior to publication, and
restricted access can be arranged for reviewers. Representa-
tives from Nature (Chris Gunter, Washington, USA) and The
Lancet (Virginia Barbour, London, UK) gave the perspective
of journals dealing with microarray data submissions and
the way in which the journals are working closely with the
EBI. Although there have been a few problems, the overall
message was that the standards are working and researchers
submitting to journals and public data repositories are
making every effort to comply with them.
Tutorials by Catherine Ball (Stanford University, USA),
Jason Gonçalves (Iobion, Toronto, Canada) and H.C.C. on
behalf of the Normalization working group discussed - for
the first time at an MGED meeting - the analysis problems
that are particularly relevant to data acquired using
Affymetrix chips, in recognition of the fact that approxi-
mately half of the attendees were generating, managing or
analyzing data from the Affymetrix platform. The working
group has not yet proposed standards for describing data
transformations used in analysis, although the Bioconductor
project [http://www.bioconductor.org], described by Rob
Gentleman (Harvard University, Boston, USA) and Sandrine
Dudoit (University of California, Berkeley, USA) may offer a
way forward. Bioconductor is an open-source project that
currently contains 30 packages for microarray data analysis
and uses the language ‘R’. Gentleman described the concept
of ‘compendia’ - self-contained objects that contain code,
text about what the code does, data on which the code oper-
ates and information on conventions. Compendia could be
used to describe the formulae used for data transformation,
the data on which the transformation is effected and a
description. A group that wanted to transform its data in the
same way as another group could simply use the same com-
pendium with its own data, or run a similar analysis in
which some of the parameters are changed. 
One obstacle to using Bioconductor for analyzing large
datasets has been the lack of resources for porting the data
from MAGE-ML into the required format. A solution was
presented by Joke Allemeersch (University of Leuven,
Belgium), who has created a package that extracts cDNA
microarray data (other array types are not included in the
current version) from a MAGE document and maps it to Bio-
conductor objects for further analysis. 
Biological insights
Many diseases are associated with quantitative and qualita-
tive changes in plasma proteins, and plasma represents the
largest and most accessible subset of the human proteome: it
contains thousands of distinct proteins, including glycopro-
teins, tissue proteins and immunoglobulins, with an extraor-
dinary dynamic range of more than 10 orders of magnitude.
Leigh Anderson (Plasma Proteome Institute, Washington,
USA) described the potential of the plasma proteome for
disease diagnosis and therapeutic monitoring. Apart from
the need to identify co-varying set of proteins and the condi-
tions with which they are associated, the major challenge
resides in the development of proteomics technologies to
identify and quantify potential markers. Classical pro-
teomics tools, such as two-dimensional gel electrophoresis,
mass spectrometry and antibody microarrays, typically
detect proteins over a dynamic range approximately 107
times smaller than the variation in individual protein abun-
dance found in plasma. New technologies are emerging,
however, which should bridge the gap between discovery of
polypeptide abundance patterns and their use as robust
diagnostic biomarkers. Anderson emphasized the need to
put sufficient disease biomarkers into the public domain, to
avoid a bottleneck in the development of diagnostic arrays.
Tony Lee (Whitehead Institute, Cambridge, USA) and Dave
Vetrie (Sanger Centre, Cambridge, UK) both presented
genome-wide protein-location analysis data (the method for
obtaining these data is also known as chromatin immuno-
precipitation on a chip - or ChIP on a chip). This technique,
which permits protein-DNA interactions to be characterized,
was used by Richard Young’s group at the Whitehead Insti-
tute to identify the target genes of 290 known protein tran-
scriptional regulators in the baker’s yeast, Saccharomyces
cerevisiae. Over 5,000 interactions were identified and most
gene promoters were found to be bound by several protein
regulators. This information was used to build elegant net-
works of interactions between genes and regulators.
‘Network motifs’ - distinct ways in which genes and proteins
regulate each other, such as feedback, autoregulatory, feed-
forward and multicomponent loops - were then assembled
into larger networks by combining genome-wide location
and expression data. The challenge in using this technique in
higher eukaryotes is not only the size of the genome, but also
the quality and accuracy of the annotation, the availability of
promoter or intergenic region microarrays, and the vast
number and heterogeneity of tissues and cell types. Vetrie
has successfully tackled many of these technical challenges
and talked about the high-resolution genomic arrays his
group has developed: these either cover specific regions of
interest and can be used for both expression and location
analysis or are designed for comparative genome hybridiza-
tion. These microarrays can be used to detect single exon
deletions (at a resolution of 100-500 base-pairs) with 99.9%
accuracy. A number of diseases are associated with single
exon deletions and Vetrie’s group intends to develop arrays
for their diagnosis.
In many ways this was a landmark meeting. A group that
began with the modest aim of sharing data and developing
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Genome Biology 2003, 4:351standards for databases has grown into a body that has cap-
tured the imagination of the functional genomics community
and represents a continuing ‘work in progress’. Most
research groups are still not able to share high-throughput
functional genomics data in any meaningful way, but the
good news is that we are well on the way to making this a
reality and can begin to carry out more sophisticated analy-
sis. Progress has been fast: as one attendee remarked, “A
year ago we were talking about MAGE-ML tools; now we
have them.” Standards are in place and widely accepted, and
there is a profusion of data-analysis software. By next year
we should be able to see the impact of these tools in action.
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